Chairman and CEO Amir Heshmatpour acquired approximately $300,000 of NTHI common stock in April 2026. The company clarified its 2025 financial results, noting a $62 million net loss, of which $45.2 million were non-cash or non-recurring charges. Normalized cash operating expenses for 2025 were approximately $10.1 million. The company completed a $13 million private placement in Q1 2026 to strengthen its balance sheet. Key clinical catalysts include a NEO212 FDA meeting in 4 weeks and a NEO100 interim data readout in 4 months.